Role of depression in quality of life for patients with psoriasis

Dermatology

Volumn 215, Issue 1, 2007, Pages 17-27

  Schmitt, Jochen M ^a,c,d   Ford, Daniel E ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Depression; Psoriasis; Quality of life; Severity of illness index; Stress, illness related

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VALIDATION PROCESS;

ADULT; AGE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; PROGNOSIS; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SICKNESS IMPACT PROFILE; STRESS, PSYCHOLOGICAL;

EID: 34250805302     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102029     Document Type: Article

References (65)

1. Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121-128.
2. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ: The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005;52:23-26.
3. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, Clark AR: The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564-569.
4. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-139.
5. de Korte J, Sprangers MA, Mombers FM, Bos JD: Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-147.
6. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaquetype psoriasis: a randomised trial. Lancet 2001;357:1842-1847.
7. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255.
8. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-3080.
9. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-2022.
10. Stern RS: A promising step forward in psoriasis therapy. JAMA 2003; 290: 3133-3135.
11. Schmitt-Egenolf M: Psoriasis therapy in real life: the need for registries. Dermatology 2006;213:327-330.
12. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-285.
13. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B: Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002;82:108-113.
14. Markham T, Watson A, Rogers S: Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol 2002;27:111-114.
15. Rapp SR, Feldman SR: The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol Ther 2004;17:376-382.
16. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-407.
17. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE: Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997;137:755-760.
18. Sampogna F, Picardi A, Chren MM, Melchi CF, Pasquini P, Masini C, Abeni D: Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 2004;66:620-624.
19. Gupta MA, Gupta AK, Schork NJ, Ellis CN: Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 1994;56:36-40.
20. Renzi C, Picardi A, Abeni D, Agostini E, Baliva G, Pasquini P, Puddu P, Braga M: Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002;138:337-342.
21. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
22. Khilij FA, Gonzalez M, Finlay AY: Clinical meaning of change in Dermatology Life Quality Index Scores. Br J Dermatol 2002;147(suppl 62):50.
23. Lewis V, Finlay AY: 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004;9:169-180.
24. Radloff LS: The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
25. Houston TK, Cooper LA, Vu HT, Kahn J, Toser J, Ford DE: Screening the public for depression through the Internet. Psychiatr Serv 2001;52:362-367.
26. Schulberg HC, Saul M, McClelland M, Ganguli M, Christy W, Frank R: Assessing depression in primary medical and psychiatric practices. Arch Gen Psychiatry 1985;42:1164-1170.
27. Thomas JL, Jones GN, Scarinci IC, Mehan DJ, Brantley PJ: The utility of the CES-D as a depression screening measure among low-income women attending primary care clinics. The Center for Epidemiologic Studies-Depression. Int J Psychiatry Med 2001;31:25-40.
28. Beekman AT, Deeg DJ, Van Limbeek J, Braam AW, De Vries MZ, Van Tilburg W: Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in The Netherlands. Psychol Med 1997;27:231-235.
29. Parikh RM, Eden DT, Price TR, Robinson RG: The sensitivity and specificity of the Center for Epidemiologic Studies Depression Scale in screening for post-stroke depression. Int J Psychiatry Med 1988;18:169-181.
30. Gupta MA, Gupta AK: The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 1995;75:240-243.
31. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE: Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res 1997;42:467-475.
32. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Exum ML, Clark AR, Nurre L: The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996;106:183-186.
33. Feldman SR, Clark AR, Venkat AP, Fleischer AB Jr, Anderson RT, Rajagopalan R: The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol 2005;152:382-383.
34. Fleischer AB Jr, Rapp SR, Reboussin DM, Vanarthos JC, Feldman SR: Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol 1994;102:967-969.
35. Fleischer AB Jr, Feldman SR, Dekle CL: The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 1999;26:210-215.
36. Sampogna F, Sera F, Mazzotti E, Pasquini P, Picardi A, Abeni D: Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol 2003;139:353-358.
37. Fredriksson T, Pettersson U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-244.
38. Stata Corporation: Stata 8 Reference Manual. College Station, 2003.
39. Stata Corporation: Stata Statistical Software: Release 8.0. College Station, 2002.
40. Joinson A: Social desirability, anonymity, and Internet-based questionnaires. Behav Res Methods Instrum Comput 1999;31:433-438.
41. Durant LE, Carey MP, Schroder KE: Effects of anonymity, gender, and erotophilia on the quality of data obtained from self-reports of socially sensitive behaviors. J Behav Med 2002;25:438-467.
42. Kelley E, Moy E, Stryer D, Burstin H, Clancy C: The national healthcare quality and disparities reports: an overview. Med Care 2005;43:13-18.
43. Moy E, Dayton E, Clancy CM: Compiling the evidence: the National Healthcare Disparities Reports. Health Aff (Millwood) 2005;24:376-387.
44. Baker L, Wagner TH, Singer S, Bundorf MK: Use of the Internet and e-mail for health care information: results from a national survey. JAMA 2003;289:2400-2406.
45. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA: Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003;1:53.
46. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ: Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-708.
47. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284.
48. Russo PA, Ilchef R, Cooper AJ: Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004;45:155-159.
49. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S: An Italian study on psoriasis and depression. Dermatology 2006;212:123-127.
50. Consoli SM, Rolhion S, Martin C, Ruel K, Cambazard F, Pellet J, Misery L: Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis. Dermatology 2006;212:128-136.
51. Diagnostic and Statistical Manual of Mental Disorders. Washington, American Psychiatric Association, 2000.
52. Gupta MA, Gupta AK: Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-850.
53. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN: Suicidal ideation in psoriasis. Int J Dermatol 1993;32:188-190.
54. Cooper-Patrick L, Crum RM, Ford DE: Identifying suicidal ideation in general medical patients. JAMA 1994;272:1757-1762.
55. Olfson M, Lewis-Fernandez R, Weissman MM, Feder A, Gameroff MJ, Pilowsky D, Fuentes M: Psychotic symptoms in an urban general medicine practice. Am J Psychiatry 2002;159:1412-1419.
56. Alpsoy E, Ozcan E, Cetin L, Ozgur O, Er H, Yilmaz E, Karaman T: Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol 1998;38:197-200.
57. Cox NH, Gordon PM, Dodd H: Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. Br J Dermatol 2002;146:1061-1063.
58. Hemlock C, Rosenthal JS, Winston A: Fluoxetine-induced psoriasis. Ann Pharmacother 1992;26:211-212.
59. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM: Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986;15:1007-1022.
60. Feldman SR: A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 2004;15:27-29.
61. Schmitt J, Wozel G: The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194-199.
62. Schmitt J, Ford DE: Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006;213:110.
63. Richards HL, Fortune DG, Weidmann A, Sweeney SK, Griffiths CE: Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004;151:1227-1233.
64. Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P: Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 2000;143:983-991.
65. Picardi A, Amerio P, Baliva G, Barbieri C, Teofoli P, Bolli S, Salvatori V, Mazzotti E, Pasquini P, Abeni D: Recognition of depressive and anxiety disorders in dermatological outpatients. Acta Derm Venereol 2004;84:213-217.